-
- Maja Narlik‐Grassow
- Experimental Therapeutics Programme Spanish National Cancer Research Centre Madrid Spain
-
- Carmen Blanco‐Aparicio
- Experimental Therapeutics Programme Spanish National Cancer Research Centre Madrid Spain
-
- Amancio Carnero
- Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/Universidad de Sevilla Sevilla Spain
書誌事項
- 公開日
- 2013-04-10
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/med.21284
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>The proviral insertion site in Moloney murine leukemia virus, or PIM proteins, are a family of serine/threonine kinases composed of three different isoforms (<jats:italic>PIM1</jats:italic>, <jats:italic>PIM2</jats:italic>, and <jats:italic>PIM3</jats:italic>) that are highly evolutionarily conserved. These proteins are regulated primarily by transcription and stability through pathways that are controlled by Janus kinase/Signal transducer and activator of transcription, JAK/STAT, transcription factors. The PIM family proteins have been found to be overexpressed in hematological malignancies and solid tumors, and their roles in these tumors were confirmed in mouse tumor models. Furthermore, the PIM family proteins have been implicated in the regulation of apoptosis, metabolism, cell cycle, and homing and migration, which has led to the postulation of these proteins as interesting targets for anticancer drug discovery. In the present work, we review the importance of PIM kinases in tumor growth and as drug targets.</jats:p>
収録刊行物
-
- Medicinal Research Reviews
-
Medicinal Research Reviews 34 (1), 136-159, 2013-04-10
Wiley